Department of Preclinical Development and Validation
Expert reports: Research and development in immuno-oncology
Identification of new diagnostic biomarkers and therapeutic targets for triple-negative breast cancer
Development of therapeutic antibodies against validated new target molecules
Development of antibody-drug conjugates
Development of chimeric antigen receptors
Development and validation of special in-vitro models (cell lines, tumoroid models) and in-vivo models (e.g., huCD34+ humanised mouse, PBMC humanised mouse, humanised tumour mouse models, CDX and PDX mouse models)